This is a competing continuation for a grant entitled "Biomarkers of Cognitive Decline among Normal Individuals: The BIOCARD Cohort'(see FOA: PAR-13-148). The BIOCARD study is a longitudinal, observational study of 349 individuals who were cognitively normal and primarily middle aged (mean age=57.1) at enrollment. By design, more than two-thirds had a family history of Alzheimer's disease (AD). The primary goal was to follow individuals from normal cognition to mild cognitive impairment (MCI) or dementia, so that it would be possible to identify biomarkers that predicted progression. The rationale for this study design is that several lines of evidence indicate that AD pathophysiological processes begin to develop many years, if not decades, before AD dementia is diagnosed. This long prodromal phase provides a 'window of opportunity'during which symptoms are minimal (if present at all) but therapeutic intervention may have the greatest opportunity of success. The BIOCARD study is in a unique position to examine 'preclinical AD', since the participants: (1) have been followed for up to 18 years (mean follow-up = 12.1 yrs), (2) are entering a period of accelerating risk, and (3) 63 of those alive have developed mild cognitive impairment (MCI) or dementia. Our overall objectives are to further advance the study of preclinical AD by: (1) clarifying the pattern and rate of changes in AD biomarkers (including CSF, MRI, amyloid imaging and blood) and cognition that occur, as well as evaluate potential new biomarkers, (2) maximizing our data by working collaboratively with several research groups who have comparable data, and (3) providing a publicly accessible database, to include biological specimens, for researchers in the field. The long duration of follow-up for the cohort is based on the fact that the study was established in 1995 by investigators in the intramural program of the NIH. The study was stopped for administrative purposes in 2005. Our investigative team was funded in July 2009 to re-enroll the participants and re-initiate longitudinal data collection. Wit this application, we are requesting funds to continue the longitudinal clinical and cognitive assessment of the cohort, collect more CSF, more MRI scans, and to initiate acquisition of positron emission tomography (PET), using [11-C] PiB, in the participants who remain cognitively normal (n=201). Though a number of studies around the world have begun to examine cognitively normal individuals with similar goals in mind, no study, to our knowledge, has up to 18 years of accumulated longitudinal data on changes in cognitive, CSF, and MRI measures first obtained when the subjects were cognitively normal and the majority were middle aged.

Public Health Relevance

The overarching goal of the research is to improve our understanding of the earliest stages at which Alzheimer's disease develops. Interventions may have the greatest opportunity of success if it is possible to identify people in the earliest phase of disease and treat them. The major goal of the study is to identify factors that predict cognitiv decline among normal individuals who were in middle age when first evaluated.

National Institute of Health (NIH)
National Institute on Aging (NIA)
Research Program--Cooperative Agreements (U19)
Project #
Application #
Study Section
Special Emphasis Panel (ZAG1-ZIJ-5 (M3))
Program Officer
Ryan, Laurie M
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Johns Hopkins University
United States
Zip Code
Onyike, Chiadi U (2016) Psychiatric Aspects of Dementia. Continuum (Minneap Minn) 22:600-14
Gross, Alden L; Mungas, Dan M; Leoutsakos, Jeannie-Marie S et al. (2016) Alzheimer's disease severity, objectively determined and measured. Alzheimers Dement (Amst) 4:159-168
Wennberg, Alexandra M V; Spira, Adam P; Pettigrew, Corinne et al. (2016) Blood glucose levels and cortical thinning in cognitively normal, middle-aged adults. J Neurol Sci 365:89-95
Soldan, Anja; Pettigrew, Corinne; Cai, Qing et al. (2016) Hypothetical Preclinical Alzheimer Disease Groups and Longitudinal Cognitive Change. JAMA Neurol 73:698-705
Pettigrew, Corinne; Soldan, Anja; Zhu, Yuxin et al. (2016) Cortical thickness in relation to clinical symptom onset in preclinical AD. Neuroimage Clin 12:116-22
Mills, Kelly A; Mari, Zoltan; Bakker, Catherine et al. (2016) Gait function and locus coeruleus Lewy body pathology in 51 Parkinson's disease patients. Parkinsonism Relat Disord 33:102-106
Soldan, Anja; Pettigrew, Corinne; Moghekar, Abhay et al. (2016) Computerized Cognitive Tests Are Associated with Biomarkers of Alzheimer's Disease in Cognitively Normal Individuals 10 Years Prior. J Int Neuropsychol Soc 22:968-977
Miller, Michael I; Ratnanather, J Tilak; Tward, Daniel J et al. (2015) Network Neurodegeneration in Alzheimer's Disease via MRI Based Shape Diffeomorphometry and High-Field Atlasing. Front Bioeng Biotechnol 3:54
Soldan, Anja; Pettigrew, Corinne; Lu, Yi et al. (2015) Relationship of medial temporal lobe atrophy, APOE genotype, and cognitive reserve in preclinical Alzheimer's disease. Hum Brain Mapp 36:2826-41
Pettigrew, Corinne; Soldan, Anja; Moghekar, Abhay et al. (2015) Relationship between cerebrospinal fluid biomarkers of Alzheimer's disease and cognition in cognitively normal older adults. Neuropsychologia 78:63-72

Showing the most recent 10 out of 31 publications